Editing Vertex Pharmaceuticals Incorporated (section)

=== Eloxx Pharmaceuticals: ===
Valued at $17.3 million and net income $36.1 million in 2022

Eloxx Pharmaceuticals is an active clinical-stage biopharmaceutical company with a focus on the discovery, development, and commercialization of compounds to address genetic diseases caused by nonsense mutations. These conditions include Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, Tay-Sachs Hurler syndrome, and many others. The company's expertise allows for a swift transition from drug discovery programs to clinical drug candidates, building a robust pipeline of molecules specifically designed for various nonsense genetic diseases. Leading the way is ELX-02, the company's flagship compound, presenting a unique opportunity as a potential disease-modifying therapy for these devastating conditions, where effective treatments are currently unavailable. As a public company founded in 2013, Eloxx Pharmaceuticals remains committed to making significant strides in the treatment of genetic diseases and improving patients' lives.